LUNDAHL SCOTT L 4
4 · DUSA PHARMACEUTICALS INC · Filed Mar 19, 2012
Insider Transaction Report
Form 4
LUNDAHL SCOTT L
VP, Regulatory Affairs & IP
Transactions
- Sale
Common Stock
2012-03-16$5.75/sh−7,976$45,862→ 220,610 total - Sale
Common Stock
2012-03-16$5.84/sh−1,600$9,344→ 211,086 total - Sale
Common Stock
2012-03-16$5.80/sh−5,224$30,299→ 213,486 total - Sale
Common Stock
2012-03-16$5.81/sh−800$4,648→ 212,686 total - Exercise/Conversion
Non-Qualified Stock Option
2012-03-16−17,500→ 0 totalExercise: $1.60From: 2007-03-13Exp: 2013-03-13→ common stock (17,500 underlying) - Sale
Common Stock
2012-03-16$5.76/sh−1,900$10,944→ 218,710 total - Exercise/Conversion
Common Stock
2012-03-16$1.60/sh+17,500$28,000→ 228,586 total
Footnotes (1)
- [F1]Includes Stock Awards which vest at the rate of one-quarter of the total grant on each of the first, second, third and fourth anniversaries of the date of the grant.